



PTO/SB/08a (07-05)

Approved for use through 07/31/2006 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/541,614
Filing Date	April 27, 2006
First Named Inventor	PATERSON, Yvonne
Art Unit	1645
Examiner Name	PORTNER, VIRGINIA ALLEN
Attorney Docket Number	P-7772-US

Sheet	1	of	2
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/V.G.P./	A	US-5,830,702	11-03-1998	Portnoy et al.	
	B	US-5,051,237	04-18-2000	Paterson et al.	
	C	US-4,256,108	03-17-1981	Theeuwes	
	D	US-4,160,452	07-10-1979	Theeuwes	
	E	US-4,265,874	05-05-1981	Bonsen et al.	
	F	US-3,328,252	06-27-1967	Mora et al.	
	G	US-2002/0177569	11-28-2002	Kaufmann et al.	
	H	US-5,628,994	05-13-1997	Kaper et al.	
/V.G.P./	I	US-5,861,163	01-19-1999	Kim et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
/V.G.P./	J	WO 01/25399	04-12-2001	Vion Pharmaceuticals Inc.		<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>

Examiner
Signature

/Ginny Portner/ (04/02/2008)

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">Application Number</td> <td>10/541,614</td> </tr> <tr> <td>Filing Date</td> <td>April 27, 2006</td> </tr> <tr> <td>First Named Inventor</td> <td>PATERSON, Yvonne</td> </tr> <tr> <td>Art Unit</td> <td>1645</td> </tr> <tr> <td>Examiner Name</td> <td>PORTNER, VIRGINIA ALLEN</td> </tr> <tr> <td>Attorney Docket Number</td> <td>P-7772-US</td> </tr> </table>		Application Number	10/541,614	Filing Date	April 27, 2006	First Named Inventor	PATERSON, Yvonne	Art Unit	1645	Examiner Name	PORTNER, VIRGINIA ALLEN	Attorney Docket Number	P-7772-US
Application Number	10/541,614																
Filing Date	April 27, 2006																
First Named Inventor	PATERSON, Yvonne																
Art Unit	1645																
Examiner Name	PORTNER, VIRGINIA ALLEN																
Attorney Docket Number	P-7772-US																
Sheet	2	of	2														

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
↓ /v.g.p./	K	BERCHE et al. (1988) "Invasiveness and intracellular growth of <i>Listeria monocytogenes</i> ." Infection 16:145-148.			
	L	FOLEY et al. (2001) "Candidatus <i>Mycoplasma haemominutum</i> , a low virulence eperythrophic parasite of cats" International Journal of Systematic and Evolutionary Microbiology, 51(3):815-817.			
	M	GOOSSENS et al. (1995), "Attenuated <i>Listeria monocytogenes</i> as a live vector for induction of CD8+ T cells in vivo: a study with the nucleoprotein of the lymphocytic choriomeningitis virus." Int. Immunol. 7:797-802.			
	N	GUNN et al. (2001) "Two <i>Listeria monocytogenes</i> vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16." J. Immunol. 167:6471-6479.			
	O	HARRIS et al. (1986) "Molecular basis for heterogeneity of the human p53 protein." Mol. Cell. Biol. 6:4650-4656.			
	P	IKONOMIDIS et al. (1997) "Influenza-specific immunity induced by recombinant <i>Listeria monocytogenes</i> vaccines." Vaccine 15:433-440.			
	Q	KAUFMANN (1993) "Immunity to intracellular bacteria" Ann. Rev. Immunol. 11:129-163.			
	R	KLEANTHOUS, H et al. (2001) "Sterilizing immunity against experimental <i>Helicobacter pylori</i> infection is challenge-strain dependent." Vaccine 19, 19(32):4883-4895.			
	S	MANKOSKI et al. (1999) "flaA mRNA transcription level correlates with <i>Helicobacter pylori</i> colonization efficiency in gnotobiotic piglets." Journal of Medical Microbiology, 48(4):395-399.			
	T	MATA et al. (2001) "Evaluation of a recombinant <i>Listeria monocytogenes</i> expressing an HIV protein that protects mice against viral challenge." Vaccine 19: 1435-1445.			
	U	MERINO et al. (2002) "A hypermutator phenotype attenuates the virulence of <i>Listeria monocytogenes</i> in a mouse model." Molecular Microbiology, 44(3):877-887.			
	V	PAN et al. (1995), "A recombinant <i>Listeria monocytogenes</i> vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours." Nat. Med. 1:471-477.			
	W	PATERSON et al. (1996) "Recombinant <i>Listeria monocytogenes</i> cancer vaccines." Curr. Opin. Immunol. 8:664-669.			
	X	SHEN et al. (1995) "Recombinant <i>Listeria monocytogenes</i> as a live vaccine vehicle for the induction of protective anti-viral cell-mediated immunity." Proc. Natl. Acad. Sci. USA 92:3987-3991.			
	Y	VAHIDY et al. (1996) "A comparative study of unpassaged and animal passaged cultures of <i>Listeria monocytogenes</i> in rabbits." Ann Acad Med. Singapore 25:139-553.			
Examiner Signature		/Ginny Portner/ (04/02/2008)			Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
 If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.